Home › Leucemia mieloide acuta › New Jersey › Newark
Studi clinici su Leucemia mieloide acuta a Newark, NJ
12 studi su Leucemia mieloide acuta cercano partecipanti presso sedi a Newark e dintorni (entro circa 30 miglia). Apri uno studio per vedere chi può partecipare e come contattare il team.
Testo ufficiale dello studio (inglese)
Stai reclutando per uno studio? Mettilo in evidenza in cima alla pagina — $99 per 30 giorni →
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
In reclutamentoStudio osservazionaleVolontari sani benvenuti
- Morristown Medical Center, Morristown · a 17 mi di distanza
Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)
In reclutamentoFase 2
- Cooperman Barnabas Medical Center, Livingston · a 9 mi di distanza
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
In reclutamentoFase 2
- Cooperman Barnabas Medical Center, Livingston · a 9 mi di distanza
Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)
In reclutamentoFase 2
- Cooperman Barnabas Medical Center, Livingston · a 9 mi di distanza
Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)
In reclutamentoFase 2
- Cooperman Barnabas Medical Center, Livingston · a 9 mi di distanza
Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)
In reclutamentoFase 2
- Cooperman Barnabas Medical Center, Livingston · a 9 mi di distanza
A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations
In reclutamentoFase 3
- Newark Beth Israel Medical Center, Newark
- Morristown Medical Center, Morristown · a 17 mi di distanza
Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML
In reclutamentoFase 1/2
- Atlantic Health, Morristown · a 17 mi di distanza
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
In reclutamentoFase 1/2
- Morristown Medical Center, Morristown · a 17 mi di distanza
Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)
In reclutamentoFase 3
- Morristown Medical Center, Morristown · a 17 mi di distanza
L-Annamycin for Injection in Combination With Cytarabine Injection as Second Line Therapy for Remission Induction in Adult Subjects With Refractory/Relapsed AML
In reclutamentoFase 2/3
- Atlantic Health, Morristown · a 17 mi di distanza
A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
In reclutamentoFase 1/2
- Atlantic Health, Morristown · a 17 mi di distanza
Studi su Leucemia mieloide acuta in altre città
- Houston, TX85 studi
- New York City, NY51 studi
- Boston, MA44 studi
- Baldwin Park, CA40 studi
- Seattle, WA40 studi
- Columbus, OH35 studi
- Philadelphia, PA34 studi
- Durham, NC33 studi
- Atlanta, GA30 studi
- Tampa, FL29 studi
- Chicago, IL26 studi
- Portland, OR25 studi
Altri studi a Newark
- Cancro al seno18 studi
- Cancro del polmone non a piccole cellule14 studi
- Lesioni del midollo spinale13 studi
- Cancro metastatico10 studi
- Insufficienza cardiaca10 studi
- Cancro pancreatico9 studi
- Malattie cardiovascolari9 studi
- Melanoma8 studi
- Cancro ai polmoni7 studi
- Cancro (tutti i tipi)7 studi
- Malattia di Crohn7 studi
- Ictus6 studi
Fonte: ClinicalTrials.gov, dati recuperati il 5 ott 2026. Ogni studio stabilisce i propri criteri di idoneità; è il team di ricerca a decidere chi può partecipare.